About Us

Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine


The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.

Since the latest edition of Baselworld, in 2015, it also features a new in-house movement, the Calibre MT5612. And it leads us to this simple conclusion: there will be more variations of this movement in the coming years! replicawatches.to Therefore, we imagined the first one, will be with a GMT complication, something that we know to be extremely useful and rather applauded by potential clients – and that its missing in the actual Tudor catalogue (indeed, theres no GMT watches in the current Tudor line up). We also know that the base movement can easily accept extra-complications, like its the case with the North Flag, which features a power reserve.

Latest News


First Patient in New Zealand Dosed with Illuccix® – Telix’s Prostate Cancer Imaging Agent

Melbourne – 30 September 2022. First Patient in New Zealand Dosed with Illuccix® – Telix’s Prostate Cancer Imaging Agent


Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate

Melbourne  – 28 September 2022. Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate


First Patient in Australia Dosed with Illuccix® – Telix’s Approved Prostate Cancer Imaging Agent 

Melbourne – 28 September 2022. First Patient in Australia Dosed with Illuccix® – Telix’s Approved Prostate Cancer Imaging Agent 


First Patient Enrolled in ProstACT TARGET Study

Melbourne  – 27 September 2022. First Patient Enrolled in ProstACT TARGET Study